I agree finishing the BLA will help everything. CYDY has been in BLA limbo for 6 months after part 1 was submitted in March, TNBC limbo for 8 months really with the NC conference in January , mono limbo for 4 mono after the pivotal trial submitted in May, and partnership/financing limbo for a year while they continue to use Paulson. I understand the frustration of some, but all of that ends soon. Getting Part 2 of the BLA done will greatly help. Mono meeting shortly, lasted September or early October. TNBC screening at least some progress. Partnership, cydy has accepted one at least, waiting on the other company dd or milestone sounds like, and others interested. With NP saying they are working on financing to the end of the year, that is when the BLA will be done, worst timeline, and probably milestone payments kick in no matter if the partnership is signed tomorrow or next month. So, they are close, and finishing the BLA is key. Getting financing until that point is the second key, we will see how much they raise. Having the partnership/financing in place before or at the same time as submission to fund operations after BLA submission is the third key. Again a majority of the burn rate is spent on the current mono trial, they indicated in 10k they wanted to stop in that trial after mono pivotal is approved and data needed, for BLA is done , we will see what the fda says. The second burn rate is going to BLA, NP said, what, 50 people working on it, plus the cmo cost over the last three years to prepare for it. The other items are just small potatoes that gives us something to talk about while we wait on the big items to get done.